Adagio Medical to Present at the Small Cap Growth Virtual Investor Conference February 5th
MWN-AI** Summary
Adagio Medical Holdings, Inc. (NASDAQ: ADGM), based in Laguna Hills, California, is set to present at the Small Cap Growth Virtual Investor Conference on February 5, 2026, at 1:30 PM ET. This interactive online event hosted by VirtualInvestorConferences.com will allow participants to engage directly with Adagio’s management team, posing questions in real-time. For those unable to attend live, an archived version of the presentation will be available post-event.
Adagio Medical is a leader in the development of catheter ablation technologies specifically tailored for treating cardiac arrhythmias. The company’s innovative Ultra-Low Temperature Cardiac (ULTA) ablation technology is designed to create extensive lesions within cardiac tissue, promoting effective treatment of ventricular tachycardia (VT). The vCLAS™ Cryoablation System, a cornerstone of Adagio's offerings, is currently CE Marked in Europe and is undergoing evaluation in the U.S. through the FULCRUM-VT pivotal trial.
Recent highlights from the company include the appointment of industry veteran Sean Salmon to its Board of Directors and the successful closing of a financing round amounting to up to $50 million. Further, the preliminary results of the FULCRUM-VT study, presented in a late-breaking session at an industry conference, indicated a remarkable 97% acute effectiveness with favorable safety outcomes. The trial, which enrolled 209 patients in just eleven months, aims to secure FDA premarket approval for the vCLAS™ system by demonstrating its efficacy in drug-refractory VT treatment.
Investors are encouraged to pre-register for the conference and may also schedule 1x1 meetings on February 12 and 13 for personalized discussions. For more details about the event, visit VirtualInvestorConferences.com.
MWN-AI** Analysis
Adagio Medical Holdings, Inc. (NASDAQ: ADGM) is poised for potential growth as it prepares to present at the Small Cap Growth Virtual Investor Conference on February 5, 2026. The conference provides a unique platform for investors to engage directly with management, making this event a crucial opportunity for Adagio to highlight its advancements in catheter ablation technology for cardiac arrhythmias.
Recent developments indicate a strong upward trajectory for Adagio Medical. The appointment of Sean Salmon, a seasoned executive from Medtronic, to the Board of Directors signals a strategic enhancement in leadership that could facilitate further innovation and market penetration. Additionally, the closure of $50 million in financing from both existing and new institutional investors reflects robust confidence in the company's future endeavors and its innovative Ultra-Low Temperature Ablation (ULTA) technology.
Moreover, the preliminary results from the FULCRUM-VT pivotal study, which demonstrate an impressive 97% acute effectiveness, suggest strong potential for FDA approval of the vCLAS™ Cryoablation System. Such approval could significantly expand the device's market reach and establish Adagio as a leader in the catheter ablation sector.
Investors should take note of the forthcoming 1x1 meetings on February 12 and 13, providing an opportunity for deeper insights into the company's vision and future strategies. With the vCLAS™ already CE marked and available in Europe, successful FDA approval could catalyze a strong revenue stream in the U.S. market.
In conclusion, while market volatility remains a concern, Adagio Medical's innovative technology, recent financing success, and strategic leadership changes position it as a compelling investment opportunity. Stakeholders should monitor the outcomes of the upcoming conference and the ongoing clinical trials closely, as these developments are likely to influence stock performance in the near term.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LAGUNA HILLS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Adagio Medical Holdings, Inc. (NASDAQ: ADGM), based in Laguna Hills, CA, a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Company management will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on February 5, 2026
DATE: February 5th
TIME: 1:30 PM ET
Available for 1x1 meetings: February 12 and 13. Schedule 1x1 Meetings here
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
- Appointed industry veteran Sean Salmon, former Senior Executive from Medtronic, to Board of Directors
- Closed Financing of up to $50 million, led by existing investors and new healthcare-dedicated institutional investors
- Unveiled preliminary acute results from FULCRUM-VT Pivotal Study highlighting 97% acute effectiveness and favorable safety in late breaking session at industry conference
- Completed enrollment in only eleven months of 209 patients in the FULCRUM-VT Pivotal Clinical Trial evaluating ultra-low temperature ablation for ventricular tachycardia
About Adagio Medical Holdings
Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cardiac (ULTA) ablation technology. ULTA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. Pivotal IDE Trial.
About FULCRUM VT
FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm trial, which has fully enrolled 209 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for FDA premarket approval (PMA) for Adagio’s vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT. Adagio’s vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic VT in Europe and select other geographies but is limited to investigational use in the United States.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
CONTACTS:Debbie KasterChief Financial Officer and Chief Business Officerdkaster@adagiomedical.comVirtual Investor ConferencesJohn M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group(212) 220-2221johnv@otcmarkets.com
FAQ**
How will the recent financing of up to $50 million impact Adagio Medical Holdings Inc ADGM's ability to scale its operations and bring the vCLAS™ Cryoablation System to market in the U.S.?
What steps is Adagio Medical Holdings Inc ADGM taking to prepare for the FDA premarket approval application following the FULCRUM-VT trial results?
Can you elaborate on the potential advantages of the ULTA ablation technology developed by Adagio Medical Holdings Inc ADGM compared to existing treatments for ventricular arrhythmias?
Given the promising acute effectiveness results from the FULCRUM-VT study, what are the next milestones for Adagio Medical Holdings Inc ADGM in terms of clinical trials and product launch timelines?
**MWN-AI FAQ is based on asking OpenAI questions about Adagio Medical Holdings Inc (NASDAQ: ADGM).
NASDAQ: ADGM
ADGM Trading
4.08% G/L:
$0.99 Last:
3,317 Volume:
$0.98 Open:
